$0.52
+3.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.52
From 52W high−64.37%
Volume482375.00
Market cap$17.50M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.52
From 52W high
−64.37%
Volume
482375.00
Market cap
$17.50M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1958.9x
P/E (TTM)
—
RSI (14)
44.7
MomentumView details →
1D Return
+3.36%
YTD Return
−60.95%
SummaryUpdated Jun 1, 2026
Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Miami Beach, Florida. The company went public in September 2021 and focuses on developing treatments for psychiatric and neurological disorders. Pasithea operates as a pre-revenue biotech company conducting research and discovery activities while also planning to establish anti-depression treatment clinics that would offer ketamine infusion therapies administered by trained pharmacists.
Similar companies
Latest newsMore news →
Pasithea Therapeutics announced it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference in Vienna, Austria, on November 12-14, 2026.6d agoThe FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.110d ago